Log In to Bolder Science

Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.


Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

  • identifier


  • Recruitment Status


  • First Posted

    July 29, 2019

  • Last update posted

    September 23, 2022

Study Description

Brief summary:

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, administered intravenously (IV) in monotherapy (Arm 1) or combination (Arm 2), to determine the maximum tolerated dose (MTD) of CC-99712 guided by a Bayesian logistic regression model (BLRM). A modified accelerated titration design will also be used for Arm 1 and Arm 2. The MTD may be established separately for CC-99712 administered at Q3W and/ or Q4W schedules. The expansion part (Part B) will further evaluate the safety and efficacy of CC-99712 in monotherapy (Arm 1) or combination (Arm 2) administered at or below the MTD in selected expansion cohorts in order to determine the RP2D. One or more doses or dosing regimens may be selected for cohort expansion. All participants will be treated until confirmed disease progression per IMWG criteria, unacceptable toxicity, or participants//Investigator decision to withdraw.

  • Condition or Disease:Multiple Myeloma
  • Intervention/Treatment: Drug: CC-99712
    Drug: BMS-986405
  • Phase: Phase 1

Detailed Description


Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 160 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
  • Actual Study Start Date: August 2019
  • Estimated Primary Completion Date: December 2024
  • Estimated Study Completion Date: May 2025

Arms and interventions

Arm Intervention/treatment
Experimental: Arm 1 (CC-99712 monotherapy)
CC-99712 will be administered via intravenous (IV) infusion once per 21-days on a Once every three weeks (Q3W) schedule, and once per 28-days on a Once every four weeks (Q4W) schedule
Drug: CC-99712
Experimental: Arm 2 (CC-99712 and BMS-986405 combination)
CC-99712 will be administered as indicated above. BMS-986405 will be administered orally TIW every week during a 21-day cycle (eg, Day 1, Day 3, Day 5, Day 8, Day 10, Day 12, Day 15, Day 17, and Day 19), with 48 hours between each dose with a week
Drug: CC-99712

Drug: BMS-986405

Outcome Measures

  • Primary Outcome Measures: 1. Adverse Events (AEs) [ Time Frame: From enrollment until at least 42 days after completion of study treatment ]
    Number of participants with adverse event
  • 2. Maximum Tolerated Dose (MTD) in participants with relapsed and refractory MM [ Time Frame: Up to 28 days ]
    Is defined as the highest dose that causes DLTs in no more than 33% of patient population during the first cycle of treatment.
  • 3. Dose Limiting Toxicity (DLT) in participants with relapsed and refractory MM [ Time Frame: Up to 28 days ]
    Is defined as any of the following toxicities occurring within the DLT assessment window
  • Secondary Outcome Measures: 1. Overall Response Rate (ORR) [ Time Frame: Up to 3 years ]
    Is defined as the proportion of participants who achieve a partial response or better (eg, Partial response (PR), Very good partial response (VGPR), Complete response (CR) or sCR), according to IMWG response criteria.
  • 2. Time to Response [ Time Frame: Up to 3 years ]
    Is defined as the time from the first CC-99712 dose date to the date of first documented response (PR or better).
  • 3. Duration of Response [ Time Frame: Up to 3 years ]
    Is defined as the time from the earliest date of documented response (≥ PR) to the first documented disease progression or death, whichever occurs first.
  • 4. Progression-free Survival (PFS) [ Time Frame: Up to 3 years ]
    Is defined as the time from the first dose of CC-99712 to progressive disease (PD) or death from any cause, whichever occurs first.
  • 5. Overall Survival (OS) [ Time Frame: Up to 3 years ]
    Is defined as the time from the first dose of CC-99712 to death from any cause.
  • 6. Pharmacokinetics- Cmax [ Time Frame: Up to 3 years ]
    Maximum plasma concentration of drug
  • 7. Pharmacokinetics- Cmin [ Time Frame: Up to 3 years ]
    Minimum plasma concentration of drug
  • 8. Pharmacokinetics- AUC [ Time Frame: Up to 3 years ]
    Area under the curve
  • 9. Pharmacokinetics- tmax [ Time Frame: Up to 3 years ]
    Time to peak (maximum) serum concentration
  • 10. Pharmacokinetics- t1/2 [ Time Frame: Up to 3 years ]
  • 11. Pharmacokinetics- CL [ Time Frame: Up to 3 years ]
  • 12. Pharmacokinetics- Vss [ Time Frame: Up to 3 years ]
    Volume of Distribution
  • 13. Presence and frequency of ADA using a validated bridging immunoassay with electrochemiluminescence detection [ Time Frame: Up to 3 years ]
    Anti-CC-99712 antibodies

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria: Participants must satisfy the following criteria to be enrolled in the study: Participant (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF). Participant has a history of multiple myeloma (MM) with relapsed and refractory disease, and must: Have disease that is nonresponsive while on their last antimyeloma therapy or documented disease progression on or within 60 days from the last dose of their last antimyeloma therapy; and, Must have received at least 3 prior MM treatment regimens and, Must have received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody (eg, daratumumab); and, Should have failed treatment with or are intolerant to all established therapies. Participants must have measurable disease, including at least one of the criteria below: M-protein quantities ≥ 0.5 g/dL by sPEP or ≥ 200 mg/24 hours urine collection by uPEP or Serum FLC levels > 100 mg/L (milligrams/liter involved light chain) and an abnormal kappa/lambda (κ/λ) ratio in patients without detectable serum or urine M-protein or For participants with immunoglobulin class A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level ≥ 0.50 g/dL. Participant has an ECOG PS of 0-1. Participants must have the following laboratory values (determined by local laboratory): Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L without growth factor support for 7 days (14 days if pegfilgrastim) Platelets (plt) ≥ 75 x 10^9/L without transfusion for 7 days or plt ≥ 50 x 109/L when BM plasma cells ≥ 50%. Potassium within normal limits or correctable with supplements. Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN). Serum bilirubin ≤ 1.5 x ULN (or ≤ 2.0 x ULN for participants with documented Gilbert's syndrome). Estimated serum creatinine clearance of ≥ 60 mL/min International normalized ratio (INR) < 1.5 x ULN and activated partial thromboplastin time (APTT) < 1.5 x ULN. Females of childbearing potential (FCBP) must: Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner), one of which must be barrier, from signing the ICF, throughout the study, during dose interruptions, and for up to 42 days following the last dose of CC-99712; and Have two negative pregnancy tests as verified by the Investigator prior to starting CC-99712. Participant must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the participant practices true abstinence from heterosexual contact. The participant may not receive IP until the Investigator has verified that the result of the pregnancy test is negative. a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at Screening a negative serum or urine pregnancy test (Investigator's discretion) within 72 hours prior to Cycle 1 Day -1 of study treatment, and within 72 hours prior to Day -1 of every subsequent cycle (note that the Screening serum pregnancy test can be used as the test prior to Day -1 study treatment if it is performed within the prior 72 hours). A serum or urine pregnancy test (investigators discretion) must also be performed at the end of study for each FCBP. Avoid conceiving for 42 days after the last dose of CC-99712. Agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. This applies even if the participant practices true abstinence2 from heterosexual contact. Males must practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or a FCBP and will avoid conceiving from signing the ICF, while participating in the study, during dose interruptions, and for at least 42 days following CC-99712 discontinuation, even if he has undergone a successful vasectomy. Participant is willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: The presence of any of the following will exclude a participant from enrollment: In Part A only, participant has received prior therapy directed at BCMA including, but not limited to, antibody-drug conjugates (BCMA-ADC), bispecific T cell-engaging antibodies or molecules, or BCMA-directed T cell therapy (eg, BCMA chimeric antigen receptor [CAR] T cells). Participant has symptomatic central nervous system involvement of MM. Participant has nonsecretory MM, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis. Participants with a history of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to signing ICF. Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712. Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease. Participant had a prior chimeric antigen receptor T (CAR T) cell product ≤ 4 weeks prior to starting CC-99712. Participant had a prior systemic cancer-directed treatments or investigational modalities within 5 pharmacokinetic half-lives or 2 weeks prior to starting CC-99712, whichever is longer. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum 4 days) before treatment. Participant had major surgery ≤ 2 weeks prior to starting CC-99712. Participants must have recovered from any clinically significant effects of recent surgery. Participant is a pregnant or lactating female. Participant has known human immunodeficiency virus (HIV) infection. Participant has known history of chronic, active hepatitis B or C virus (HBV/HCV) infection. Participant requires ongoing treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors). Participant has a history of concurrent second cancers requiring active, ongoing systemic treatment. Participant has known history of cirrhosis or has clinically significant liver or biliary disease. Participants with stable chronic liver or biliary disease (such as Gilbert's syndrome, asymptomatic gallstones, or hepatobiliary involvement of malignancy) may participate in the study, however, sponsor medical monitor must be contacted for a discussion before enrollment. Participant has a history of clinically significant corneal disease requiring therapy or ongoing active corneal disease. Participant has active peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0). Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. Participant has any condition including the presence of laboratory abnormalities, such as active or uncontrolled infection, which places the participant at unacceptable risk if he/she were to participate in the study. Participant has any condition that confounds the ability to interpret data from the study. Participant has confirmed extramedullary plasmacytoma in pulmonary, cardiac, or hepatic systems. Participant has documented malabsorptive syndromes including enteropathies, gastroenteritis (acute or chronic) or diarrhea (acute or chronic) with active treatment. Participant has previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1. • Acute symptoms must have resolved and based on investigator assessment in consultation with the medical monitor, there are no sequelae that would place the participant at a higher risk of receiving study treatment. Participant has previous SARS-CoV-2 vaccine within 14 days of C1D1. For vaccines requiring more than one dose, the full series (eg, both doses of a two-dose series) should be completed at least 14 days prior to C1D1 when feasible and when a delay in C1D1 would not put the study participant at risk.

Contacts and Locations


Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:

Contact: First line of the email MUST contain NCT # and Site #.


United States, California
University of California San Diego Moores Cancer Center
La Jolla

United States, California
University Of California San Diego Moores Cancer Center
La Jolla

United States, Florida
Florida Cancer Specialists

United States, New York
Roswell Park Cancer Institute

United States, New York
Mount Sinai Hospital
New York

United States, Oregon
Oregon Health & Science University

United States, Texas
UT Southwestern Medical Center

United States, Texas
UT Southwestern Medical Center

United States, Washington
Swedish Cancer Institute

Canada, Alberta
Tom Baker Cancer Center

Canada, Ontario
Princess Margaret Cancer Centre

Canada, Quebec
Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal

Canada, Quebec
Local Institution - 201

Institut Paoli Calmettes
Marseille Cedex 9

CHU Montpellier - Hôpital Saint Eloi
Montpellier CEDEX 5

CHU Nantes Hotel Dieu

Hopital Saint Antoine

Centre Hospitalier Lyon Sud
Pierre Bénite

Institut Claudiu Regaud, IUCT-Oncopole

ASST-Ospedale di Bergamo

University of Bologna

Azienda Ospedaliero - Universitaria "Policlinico - Vittorio Emanuele" - Ospedale Vittorio Emanuele

Istituto Nazionale dei Tumori | Fondazione IRCCS

Clinic Barcelona Hospital Universitari

Hospital Universitario 12 de Octubre

Complejo Asistencial Universitario de Salamanca - H. Clinico

HUV Rocio

Hospital Universitari i Politecnic La Fe de Valencia

Sponsors and Collaborators



Study Director: Eric Kim, MD Celgene

More Information

  • Responsible Party: Celgene
  • Identifier: NCT04036461 History of Changes
  • Other Study ID Numbers: CC-99712-MM-001, U1111-1231-9404, 2020-004514-35
  • First Posted: July 29, 2019 Key Record Dates
  • Last Update Posted: September 23, 2022
  • Last Verified: September 2022
  • Individual Participant
    Data (IPD) Sharing

  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL:
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: Multiple Myeloma
    Relapsed and refractory
    Antibody drug conjugate
  • Additional relevant MeSH terms: Multiple Myeloma
    Neoplasms, Plasma Cell
    Neoplasms by Histologic Type
    Hemostatic Disorders
    Vascular Diseases
    Cardiovascular Diseases
    Blood Protein Disorders
    Hematologic Diseases
    Hemorrhagic Disorders
    Lymphoproliferative Disorders
    Immunoproliferative Disorders
    Immune System Diseases